Dr. Kent Holtorf and the Integrative Peptide Protocol

Note: This is part 4 of 4 where I map the major thinkers in CIRS and mold-related illness: what each one believes, where each one is strong, and where each one breaks down.

Introduction: I argued that the four major camps of CIRS treatment aren’t actually contradicting each other. Each one is answering the same question in a different way: Where is the illness?
Part One: Does the Shoemaker Protocol Work? This post looks at the camp that addresses the question through scientific inquiry.
Part Two: Addressing the needs of the CIRS patient. We took a look at Dr. Neil Nathan and Dr. Jill Crista, two clinicians who focus on the most sensitive patients.
Part Three: Mycotoxins and the immune response. Examining the diagnostic method of Dr. Andrew Campbell, a clinician who looks at the immune system’s antibodies response.
Part Four: This post takes a look at Dr. Kent Holtorf and his argument that mold illness isn’t actually about the mold.

The first three camps, for all their differences, share the assumption that the mold did something to the patient:

• Dr. Ritchie Shoemaker measures the inflammation it triggered,
• Dr. Neil Nathan and Dr. Jill Crista manage the sensitivity it left behind
• Dr. Andrew Campbell measures the antibodies it provoked

All of them treat the toxin as the prime mover.

Dr. Kent Holtorf says they’re all looking in the wrong place.

His argument is the most provocative in the field, and for a clinic like mine, which is built around the most complex, sensitive patients, it’s also the one I can least afford to ignore.

*Note: this blog was written by me, Mark Volmer. All spelling mistakes, misquotes, errors, and omissions are my own doing. It is not AI generated. *

Expert Recap: Dr. Kent Holtorf and Integrative Peptides

Dr. Kent Holtorf does not believe mold is the cause of the immune dysregulation behind mold illness, or CIRS. Instead, Dr. Holtorf claims that the immune dysregulation was already present, and mold is only the trigger that caused CIRS. His treatment focuses on correcting the immune system, so it can clear out the toxins and get rid of the inflammation on its own. He uses peptides to nudge cells back towards normal function, instead of forcing them.

His claims are worth examination as many ring true. However, the basis of Dr. Holtorf’s claims are limited trials that he has controlled. He also owns the product line that his patients are directed to purchase from. Finally, his attacks on the Shoemaker protocol do not hold up under scrutiny. So while he has some valid points, they are not backed up by science.

Where Dr. Holtorf says the illness lives

Recall our original question: Where, exactly, is the illness?

Dr. Holtorf’s answer? It’s in the immune system, not the mold. He says the illness is a pre-existing immune dysfunction that the patient was already carrying. The mycotoxin exposure was merely the tipping point that shoved an already-fragile system over the edge.

This reframe has real explanatory power, and it’s worth sitting with. It explains the question every mold clinician eventually confronts: Why does one person get so sick from a building when others are untouched?

Dr. Shoemaker blames genetics (the HLA anomaly).

Dr. Holtorf blames the susceptible patient’s immune system. He believes the patient’s immune system was already compromised, and the mold simply exposed and amplified what was there.

He uses a recurring patient, “Sarah,” to illustrate his point. Sarah has been compliantly following the Shoemaker protocol for years, but her TGF-β1 biomarker is still stubbornly high and she is still sick. Dr. Holtorf’s diagnosis of Sarah’s situation is that while the Shoemaker protocol was chasing biomarkers, her profoundly dysfunctional immune system went untouched. His metaphor: you can’t mop a flooded basement while the dam upriver is still broken.

The engine, in detail

This is where Dr. Holtorf is genuinely more mechanistically sophisticated than the other camps, and it’s worth understanding even if you end up skeptical of the conclusions. He describes the immune dysfunction as four interlocking failures:

T-cell exhaustion

T-cells are the part of the adaptive immune system. The adaptive immune system creates specific antibodies for invaders, so you won’t catch the same virus or bacteria twice. The job of T-cells is to recognize and respond to the invaders. Ongoing mycotoxin exposure, plus the reactivation of latent viruses results in T-cell exhaustion. A critical arm of adaptive immunity goes functionally dark.

No new T-cells

New T-cells are trained in the thymus. Mycotoxins are directly toxic to the thymus, so as the thymus shrinks, the body is not able to create new T-cells to counter new threats. As a result, the current T-cells are exhausted and there are no new ones coming in to replace them.

The immune seesaw

Part of the immune system is suppressed, leaving the patient unable to control viruses or clear toxins. Another part of the immune system goes into overdrive, resulting in hypersensitivity and inflammation. He argues this single imbalance accounts for most CIRS symptoms.

Suppression of natural killer cells

Natural killer (NK) cells are the rapid-response force against viruses and malignant cells in the innate immune system. Even a tiny amount of mycotoxins can suppress their activity.

This is a coherent and biologically literate explanation about why a subset of patients stay sick. It takes the immune dysfunction that Shoemaker’s model acknowledges but treats as downstream, and promotes it to the lead role.

The treatment: restore the regulator, not manage the toxin

If the problem is a broken immune system, it follows that the immune system should be repaired first. A restored immune system can then clear the toxins, control the infections, and quench the inflammation on its own. Dr. Kent Holtorf calls this an “inside-out” model, and his tool of choice is peptides. Peptides are short amino acid chains that act as signalling molecules, nudging cells back toward normal function rather than forcing them.

His protocol, the unfortunately-named Holtorf Updated Peptide Protocol for the Rapid Treatment of CIRS (HUPPRTOC), is sequenced as follows:

1. Restore thymic function
2. Reverse T-cell exhaustion
3. Heal the gut and blood-brain barriers
4. Restore mitochondrial energy
5. Let downstream resolution take care of itself.

He uses the following peptides:

• Thymic peptides Vilon, Thymogen, Thymogen Alpha-1, TB4 fragment to rebuild T-cell production and rebalance the immune  seesaw. They are claimed to directly inhibit TGF-β1.
• Barrier and gut-brain peptides BPC-157 for mucosal and blood-brain barrier repair; KPV, an MSH fragment, for mast-cell inhibition and antimicrobial action.
• Pineal peptides Epitalon, Pinealon to reset the neuroendocrine axis, sleep, and circadian rhythm.
• Mitochondrial peptides MOTS-c, SS-31, Humanin to restore the cellular energy that detoxification and immune function both require.

Dr. Kent Holtorf vs Dr. Shoemaker

The treatment Dr. Kent Holtorf proposed is in direct opposition to the Shoemaker protocol.

Binders. Cholestyramine (CSM) is the approved binder for the Shoemaker protocol. Dr. Kent Holtorf calls CSM “marginally beneficial, fraught with numerous side effects, and poorly tolerated,”. He notes that it is often prescribed for years without meaningful improvement, and refers to it as a passive “mopping up” that never addresses why the body can’t clear toxins itself. He replaces binding with peptides that offer cellular protection, in addition to a mitochondrial-enabled natural detox.

TGF-β1. Dr. Shoemaker uses losartan, which is a repurposed blood-pressure drug to lower TGF-β1. It is introduced late in the protocol and for a limited window of time. Dr. Holtorf’s peptides target TGF-β1 directly and from the outset.

VIP. This claim is the most controversial, and it deserves its own scrutiny.

The VIP claim — where I push back

VIP (vasoactive intestinal peptide) is the final step of the Shoemaker protocol, and the therapy patients work toward for months. Dr. Holtorf argues VIP is not just unnecessary but dangerous. He claims that in the high-TGF-β1 inflammatory state of CIRS, VIP becomes pro-inflammatory, induces T-cell exhaustion, suppresses NK function, and raises cancer risk. Dr. Holtorf says that any symptom relief experienced by patients is a mask over “progressive immune deterioration.”

I use VIP clinically and carefully in appropriate patients, after removal from exposure and after the inflammatory markers have been brought down. I believe Dr. Holtorf’s claim about VIP is the weakest link in an otherwise interesting argument.

Here’s the problem: the claim is asserted, not demonstrated. Dr. Holtorf presents the claim that VIP is a cancer risk and contributes to immune deterioration. However, he offers no controlled human data showing that VIP therapy, when administered correctly in the Shoemaker protocol, produces worse outcomes, T-cell exhaustion, or cancer in real CIRS patients.

The timing of a patient being administered VIP matters enormously, and it’s the part Dr. Holtorf’s claim quietly omits. In the Shoemaker protocol, VIP is the last step. This is because the preceding steps have removed the exposure and lowered the inflammation, making VIP use safe.

Proper adherence to the Shoemaker protocol ensures that VIP is not administered if the patient is in a raging high TGF-β1 state. Dr. Holtorf isn’t wrong – VIP should not be used to paper over an active, unaddressed inflammatory state. However, his criticism of VIP is not of VIP itself, but of the improper timing of its use.

When a safety allegation this serious is leveled at a rival’s signature therapy, the burden is on the accuser to show the harm in the population being treated. That burden hasn’t been met here.

Where Dr. Holtorf’s claims break more broadly

Dr. Holtorf’s claim about VIP is one instance of a pattern that runs through his whole framework, and it’s the pattern that keeps me from jumping into the Dr. Kent Holtorf camp.

The certainty outruns the evidence.

The language is the tell: “revolutionary,” “paradigm shift,” “rapid,” “superior efficacy,” “exceptional safety profile.” But the peptides at the center of it — BPC-157, TB4, the thymic and pineal bioregulators — are largely unapproved, research-status compounds with limited human trial data for these specific uses. “Exceptional safety profile” is asserted, but it is not shown with long-term human safety studies.

The longevity evidence is thin and narrowly sourced.

The supporting data for the pineal and thymic peptides leans heavily on Russian bioregulator research from the Khavinson/Anisimov groups in the early 2000s. This work exists, but it has not been independently replicated at scale in the West, and it is treated cautiously by the broader scientific community. The headline claims of reversing biological age by years, and dramatic telomere lengthening come from Dr. Holtorf’s own ongoing, uncontrolled programs, not from randomized controlled trials.

He doesn’t transcend biomarkers — he swaps them.

There’s an irony worth noticing. Dr. Holtorf criticizes the reliability of Dr. Shoemaker’s biomarkers, then offers NK cell activity and an expanded coagulation panel as more reliable alternatives. He’s still measuring; he just prefers his own instruments.

The protocol is also a product line.

This is the part every patient should examine closely. Halfway through the document that lays out the science, the focus turns into longevity marketing and direct promotion of Dr. Holtorf’s own peptide company, his clinic, and specific named products. I’m not suggesting the science is invented to sell the peptides. But when the person describing the disease, defining the protocol, and selling the compounds is the same person, a patient should know where the science ends and the profit begins. The relentless optimism of the narrative makes more sense considering there are products to sell. A patient should weight the bold claims accordingly.

What I take from Dr. Kent Holtorf

Here’s my honest position, and it’s genuinely split.

I think Holtorf is right about the biology and overconfident about the cure. He has correctly identified the thing the Shoemaker model underweights: a real, mechanistically describable immune dysfunction that helps explain why a specific population — the reactive, the chronically infected, the long-haul non-responders — stays sick no matter how faithfully they run the standard protocol. That population is precisely who walks into my clinic. And several of his tools are genuinely useful for them: BPC-157 for barrier repair, KPV for mast-cell and antimicrobial action, the mitochondrial peptides for the energy floor — these have plausible mechanisms and real clinical signal in the right hands.

Where I get off the train is the leap from “these tools help” to “this is a paradigm shift that replaces the foundation.” The peptides are an addition to my toolkit for difficult cases, not a wholesale substitute for an objective, validated, sequenced framework. The “rapid” and “superior” and “replaces VIP” claims run ahead of the data. And the commercial machinery surrounding the protocol is a reason for more caution, not less.

So I borrow the tools and I distrust the certainty. For a non-responder who has stalled on the standard approach, peptides aimed at the immune and mitochondrial terrain can be exactly what’s needed — used as a careful adjunct, with the same objective markers I’d use anyway, and without the promise that we’ve found the one true engine of the disease.